Anderson Jason H, Tester David J, Will Melissa L, Ackerman Michael J
From the Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine (J.H.A., M.J.A.), Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory (D.J.T., M.L.W., M.J.A.), and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN (M.J.A.).
Circ Cardiovasc Genet. 2016 Jun;9(3):259-65. doi: 10.1161/CIRCGENETICS.115.001370. Epub 2016 Apr 25.
Targeted postmortem genetic testing of the 4 major channelopathy-susceptibility genes (KCNQ1, KCNH2, SCN5A, and RYR2) have yielded putative pathogenic mutations in ≤30% of autopsy-negative sudden unexplained death in the young (SUDY) cases with highest yields derived from the subset of exertion-related SUDY. Here, we evaluate the role of whole-exome sequencing in exertion-related SUDY cases.
From 1998 to 2010, 32 cases of exertion-related SUDY were referred by Medical Examiners for a cardiac channel molecular autopsy. A mutational analysis of the major long-QT syndrome-susceptibility genes (KCNQ1, KCNH2, and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene (RYR2) identified a putative pathogenic mutation in 11 cases. Whole-exome sequencing was performed on the remaining 21 targeted gene-negative SUDY cases. After whole-exome sequencing, a gene-specific surveillance of all genes (N=100) implicated in sudden death was performed to identify putative pathogenic mutation(s). Three of these 21 decedents had a clinically actionable, pathogenic mutation (CALM2-F90L, CALM2-N98S, and PKP2-N634fs). Of the 18 remaining cases, 7 hosted at least 1 variant of unknown significance with a minor allele frequency <1:20 000. The overall yield of pathogenic mutations was higher among decedents aged 1 to 10 years (10/11, 91%) than those aged 11 to 19 years (4/21, 19%, P=0.0001).
Molecular screening in this clinical scenario is appropriate with a pathogenic mutation detection rate of 44% using direct DNA sequencing followed by whole-exome sequencing. Only 5 of the 100 interrogated sudden death genes hosted actionable pathogenic mutations for more than one third of these exertion-related, autopsy-negative SUDY cases.
对4种主要通道病易感基因(KCNQ1、KCNH2、SCN5A和RYR2)进行靶向尸检基因检测,在≤30%的尸检阴性的年轻不明原因猝死(SUDY)病例中发现了推定的致病突变,其中与运动相关的SUDY亚组的检出率最高。在此,我们评估全外显子测序在与运动相关的SUDY病例中的作用。
1998年至2010年,32例与运动相关的SUDY病例由法医转介进行心脏通道分子尸检。对主要长QT综合征易感基因(KCNQ1、KCNH2和SCN5A)和儿茶酚胺能多形性室性心动过速易感基因(RYR2)进行突变分析,在11例病例中发现了推定的致病突变。对其余21例靶向基因阴性的SUDY病例进行全外显子测序。全外显子测序后,对所有与猝死相关的基因(N = 100)进行基因特异性监测,以确定推定的致病突变。这21例死者中有3例具有临床可操作的致病突变(CALM2-F90L、CALM2-N98S和PKP2-N634fs)。在其余18例病例中,7例至少有1个次要等位基因频率<1:20 000的意义未明的变异。1至10岁死者的致病突变总体检出率(10/11,91%)高于11至19岁死者(4/21,19%,P = 0.0001)。
在这种临床情况下进行分子筛查是合适的,使用直接DNA测序继以全外显子测序,致病突变检测率为44%。在这些与运动相关、尸检阴性的SUDY病例中,100个被检测的猝死基因中只有5个携带了对超过三分之一病例具有临床可操作意义的致病突变。